Of note, pharmaceutical inhibition of FXR significantly suppresses IL-6/IL-6ST/p-STAT3 signaling and reduces metastatic tumor burden in mouse NSCLC metastasis models, suggesting a potential therapeutic approach for this subgroup (characterized by FXRhigh) of metastatic NSCLC patients (Fig. 7). Here, IL6 is linked to non-small cell lung carcinoma.